Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights.